Elevated levels of serum IL‑36α in patients with systemic lupus erythematosus

Wang,Xue-Rong; Xiao,Jian-Ping; Wang,De-Guang

doi:10.3892/br.2021.1452

Elevated levels of serum IL‑36α in patients with systemic lupus erythematosus

Authors:
- Xue-Rong Wang
- Jian-Ping Xiao
- De-Guang Wang
View Affiliations

Affiliations: Department of Nephrology, The Second Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China
Published online on: July 23, 2021 https://doi.org/10.3892/br.2021.1452
Article Number: 76

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the levels of IL‑36α and its association with disease activity in patients with systemic lupus erythematosus (SLE). A total of 60 patients with SLE and 29 healthy controls were enrolled in the present study. Disease activity was evaluated using the SLE disease activity index (SLEDAI). The serum levels of IL‑36α, IL‑36 receptor antagonist (IL‑36Ra) and IL‑17 were assessed using ELISA. The levels of IL‑36α in patients with SLE were significantly higher compared with those of healthy controls. There was a significant increase in IL‑36α in the active SLE group (SLEDAI score ≥5) compared with that of the healthy controls (P<0.001). The serum IL‑36α levels were higher in patients with active SLE than in patients with quiescent disease (P=0.012). IL‑36Ra was downregulated in patients with SLE (P=0.007). The serum IL‑17 levels were elevated in patients with SLE (P=0.036), and a positive correlation was observed between the IL‑36α and IL‑17 levels (r=0.453, P=0.003). The serum IL‑36α levels were associated with SLEDAI (r=0.374, P=0.003), proteinuria (r=0.329, P=0.010) and complement 3 (r=‑0.336, P=0.009). Patients who were receiving glucocorticoid treatment had lower IL‑36α levels than those who were not receiving glucocorticoid treatment (P=0.003). Patients with lupus nephritis had higher serum IL‑36α levels compared with those found in patients without lupus nephritis (P=0.037). The serum IL‑36α concentration was elevated in patients with SLE, and was correlated with disease activity and IL‑17 levels. The aberrant serum IL‑36α levels observed in the present study and its clinical association with SLE suggest the important role of IL‑36α in onset and progression of SLE. In addition, the association of IL‑36α with IL‑17 level indicates its involvement in the regulation of T helper 17 cytokines.

View Figures

View References

1	van de Veerdonk FL and Netea MG: New insights in the immunobiology of IL-1 family members. Front Immunol. 4(167)2013.PubMed/NCBI View Article : Google Scholar
2	Tortola L, Rosenwald E, Abel B, Blumberg H, Schäfer M, Coyle AJ, Renauld JC, Werner S, Kisielow J and Kopf M: Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 122:3965–3976. 2012.PubMed/NCBI View Article : Google Scholar
3	Ciccia F, Accardo-Palumbo A, Alessandro R, Alessandri C, Priori R, Guggino G, Raimondo S, Carubbi F, Valesini G, Giacomelli R, et al: Interleukin-36α axis is modulated in patients with primary Sjögren's syndrome. Clin Exp Immunol. 181:230–238. 2015.PubMed/NCBI View Article : Google Scholar
4	Perry D, Peck AB, Carcamo WC, Morel L and Nguyen CQ: The current concept of T(h)17 cells and their expanding role in systemic lupus erythematosus. Arthritis (Egypt). 2011(810649)2011.PubMed/NCBI View Article : Google Scholar
5	Chen XQ, Yu YC, Deng HH, Sun JZ, Dai Z, Wu YW and Yang M: Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol. 30:221–225. 2010.PubMed/NCBI View Article : Google Scholar
6	Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, Wan L and Li M: Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 60:1472–1483. 2009.PubMed/NCBI View Article : Google Scholar
7	Gresnigt MS and van de Veerdonk FL: Biology of IL-36 cytokines and their role in disease. Semin Immunol. 25:458–465. 2013.PubMed/NCBI View Article : Google Scholar
8	Gresnigt MS, Rösler B, Jacobs CW, Becker KL, Joosten LA, van der Meer JW, Netea MG, Dinarello CA and van de Veerdonk FL: The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol. 43:416–426. 2013.PubMed/NCBI View Article : Google Scholar
9	Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, O'Toole M, Young DA, Fouser LA, Nickerson-Nutter C, Collins M, et al: Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: Implications in psoriasis pathogenesis. J Invest Dermatol. 131:2428–2437. 2011.PubMed/NCBI View Article : Google Scholar
10	Chi HH, Hua KF, Lin YC, Chu CL, Hsieh CY, Hsu YJ, Ka SM, Tsai YL, Liu FC and Chen A: IL-36 signaling facilitates activation of the NLRP3 inflammasome and IL-23/IL-17 axis in renal inflammation and fibrosis. J Am Soc Nephrol. 28:2022–2037. 2017.PubMed/NCBI View Article : Google Scholar
11	Mai SZ, Li CJ, Xie XY, Xiong H, Xu M, Zeng FQ, Guo Q and Han YF: Increased serum IL-36α and IL-36γ levels in patients with systemic lupus erythematosus: Association with disease activity and arthritis. Int Immunopharmacol. 58:103–108. 2018.PubMed/NCBI View Article : Google Scholar
12	Chu M, Wong CK, Cai Z, Dong J, Jiao D, Kam NW, Lam CW and Tam LS: Elevated expression and pro-inflammatory activity of IL-36 in patients with systemic lupus erythematosus. Molecules. 20:19588–19604. 2015.PubMed/NCBI View Article : Google Scholar
13	Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40(1725)1997.PubMed/NCBI View Article : Google Scholar
14	Bombardier C, Gladman DD, Urowitz MB, Caron D and Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35:630–640. 1992.PubMed/NCBI View Article : Google Scholar
15	Gandevia B and Tovell A: Declaration Of Helsinki. Med J Aust. 2:320–321. 1964.PubMed/NCBI
16	Towne JE, Garka KE, Renshaw BR, Virca GD and Sims JE: Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 279:13677–13688. 2004.PubMed/NCBI View Article : Google Scholar
17	Frey S, Derer A, Messbacher ME, Baeten DL, Bugatti S, Montecucco C, Schett G and Hueber AJ: The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis. 72:1569–1574. 2013.PubMed/NCBI View Article : Google Scholar
18	Debets R, Timans JC, Homey B, Zurawski S, Sana TR, Lo S, Wagner J, Edwards G, Clifford T, Menon S, et al: Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol. 167:1440–1446. 2001.PubMed/NCBI View Article : Google Scholar
19	Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, Wong WH and Bowcock AM: Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics. 13:69–78. 2003.PubMed/NCBI View Article : Google Scholar
20	Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N, Kanaly ST, Towne JE, Willis CR, Kuechle MK, et al: Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 204:2603–2614. 2007.PubMed/NCBI View Article : Google Scholar
21	Qiu F, Song L, Yang N and Li X: Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus. 22:1011–1016. 2013.PubMed/NCBI View Article : Google Scholar
22	Song L, Qiu F, Fan Y, Ding F, Liu H, Shu Q, Liu W and Li X: Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol. 33:111–117. 2013.PubMed/NCBI View Article : Google Scholar
23	Zhang M, Xu WD, Zhu Y, Wen PF, Leng RX, Pan HF and Ye DQ: Serum levels of cytokines in systemic lupus erythematosus: Association study in a Chinese population. Z Rheumatol. 73:277–280. 2013.PubMed/NCBI View Article : Google Scholar
24	Maddur MS, Miossec P, Kaveri SV and Bayry J: Th17 cells: Biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 181:8–18. 2012.PubMed/NCBI View Article : Google Scholar
25	Ichii O, Otsuka S, Sasaki N, Yabuki A, Ohta H, Takiguchi M, Hashimoto Y, Endoh D and Kon Y: Local overexpression of interleukin-1 family, member 6 relates to the development of tubulointerstitial lesions. Lab Invest. 90:459–475. 2010.PubMed/NCBI View Article : Google Scholar
26	Wong CK, Lit LC, Tam LS, Li EK, Wong PT and Lam CW: Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 127:385–393. 2008.PubMed/NCBI View Article : Google Scholar
27	Wong CK, Ho CY, Li EK and Lam CW: Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus. 9:589–593. 2000.PubMed/NCBI View Article : Google Scholar
28	Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM and Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179–189. 2006.PubMed/NCBI View Article : Google Scholar
29	Nalbandian A, Crispín JC and Tsokos GC: Interleukin-17 and systemic lupus erythematosus: Current concepts. Clin Exp Immunol. 157:209–215. 2009.PubMed/NCBI View Article : Google Scholar
30	Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL and Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441:235–238. 2006.PubMed/NCBI View Article : Google Scholar
31	Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR and Weaver CT: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 441:231–234. 2006.PubMed/NCBI View Article : Google Scholar
32	Nicklin MJ: Finally, function for ‘IL-1Fs’. Blood. 118:5713–5714. 2011.PubMed/NCBI View Article : Google Scholar
33	Towne JE, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, Gabel CA and Sims JE: Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J Biol Chem. 286:42594–42602. 2011.PubMed/NCBI View Article : Google Scholar